Putative mechanisms of the relationship between obesity and migraine progression

Current Pain and Headache Reports

Volumn 12, Issue 3, 2008, Pages 207-212

  Bigal, Marcelo E ^a   Lipton, Richard B ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ARGININE; AUTACOID; BLOOD CLOTTING FACTOR 5; C REACTIVE PROTEIN; CALCITONIN GENE RELATED PEPTIDE; CYTOKINE; FIBRINOGEN; GELATINASE B; GLYCINE; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; INSULIN; INTERLEUKIN 6; LEPTIN; LIPID; OREXIN; OREXIN A; OREXIN B; PROTEIN S; RESISTIN; SEROTONIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; AMINO ACID SUBSTITUTION; AUTONOMIC DYSFUNCTION; BODY MASS; CHRONICITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; ENZYME ACTIVATION; GENE MUTATION; GENETIC RISK; HUMAN; HYPERTENSION; HYPOTHALAMUS FUNCTION DISORDER; INSULIN RESISTANCE; LIFESTYLE; MENINGITIS; METABOLIC REGULATION; METABOLIC SYNDROME X; MIGRAINE; NOCICEPTION; OBESITY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; THROMBOSIS;

ANIMALS; CHRONIC DISEASE; DISEASE PROGRESSION; HUMANS; MIGRAINE DISORDERS; OBESITY;

EID: 48749088692     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-008-0036-z     Document Type: Review

References (49)

1. Scher AI, Stewart WF, Lipton RB: Prevalence of frequent headache in a population sample. Headache 1998, 38:497-506.
2. Lipton RB, Bigal ME: Migraine: epidemiology, impact, and risk factors for progression. Headache 2005, 45(Suppl 1): S3-S13
3. Mathew NT, Reuveni U, Perez F: Transformed or evolutive migraine. Headache 1987, 27:102-106.
4. Silberstein SD, Lipton RB, Sliwinski M: Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996, 47:871-875.
5. Saper JR: The mixed headache syndrome: a new perspective. Headache 1982, 22:284-286.
6. Scher AI, Stewart WF, Ricci JA, Lipton RB: Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003, 106:81-89.
7. Katsarava Z, Muessig M, Dzagnidze A, et al.: Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2005, 25:12-15.
8. National Center for Chronic Disease Prevention and Health Promotion: Overweight and obesity: obesity trends. Available at: http://www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/index.htm. Accessed June 18, 2006.
9. Yan LL, Daviglus ML, Liu K, et al.: Midlife body mass index and hospitalization and mortality in older age. JAMA 2006, 295:190-198.
10. World Health Organization: Obesity and overweight. Global strategy on diet, physical activity, and health. Available at: http://www.who.int/dietphysicalactivity/publications/facts/obesity/en. Accessed August 19, 2006.
11. Wang Y, Mi J, Shan XY, et al.: Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond) 2007, 31:177-188.
12. Finkelstein EA, Fiebelkorn IC, Wang G: National medical spending attributable to overweight and obesity: how much, and who's paying? Health Aff 2003, Suppl Web Exclusives: W3-219-226.
13. Bigal ME, Liberman JN, Lipton RB: Obesity and migraine: a population study. Neurology, 2006, 66:545-550.
14. Bigal ME, Lipton RB: Obesity is a risk factor for transformed migraine but not for chronic tension-type headache. Neurology 2006, 67:252-257.
15. Bigal ME, Tsang A, Loder E, et al.: Body mass index and primary headaches. The AMPP study. Arch Intern Med 2007, 167:1964-1970.
16. Bigal ME, Lipton RB, Holland PR, Goadsby PJ: Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007, 68:1851-1861.
17. Peres MF, Lerário DD, Garrido AB, Zukerman E: Primary headaches in obese patients. Arq Neuropsiquiatr 2005, 63:931-933.
18. Tietjen GE, Peterlin BL, Brandes JL, et al.: Depression and anxiety: effect on the migraine-obesity relationship. Headache 2007, 47:866-875.
19. Breslau N, Lipton RB, Stewart WF, et al.: Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology 2003, 60:1308-1312.
20. Moskowitz MA, Macfarlane R: Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1993, 5:159-177.
21. Moskowitz MA: Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993, 43(Suppl 3):S16-S20.
22. Goadsby PJ, Edvinsson L: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993, 33:48-56.
23. Goadsby PJ, Macdonald GJ: Extracranial vasodilatation mediated by VIP (vasoactive intestinal polypeptide). Brain Res 1985, 329:285-288.
24. Sarchielli P, Alberti A, Baldi A, et al.: Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache 2006, 46:200-207.
25. Welch KM, Brandes AW, Salerno L, Brandes JL: C-reactive protein may be increased in migraine patients who present with complex clinical features. Headache 2006, 46:197-199.
26. Flier JS: The adipocyte: storage depot or node on the energy information superhighway? Cell 1995, 80:15-18.
27. Mohamed-Ali V, Pinkney JH, Coppack SW: Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998, 22:1145-1158.
28. Herishanu Y, Rogowski O, Polliack A, Marilus R: Leukocytosis in obese individuals: possible link in patients with unexplained persistent neutrophilia. Eur J Haematol 2006, 76:516-520.
29. Curat CA, Wegner V, Sengenes C, et al.: Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006, 49:744-747.
30. Gram DX, Hansen AJ, Wilken M, et al.: Plasma calcitonin gene-related peptide is increased prior to obesity, and sensory nerve desensitization by capsaicin improves oral glucose tolerance in obese Zucker rats. Eur J Endocrinol 2005, 153:963-969.
31. Kurth T, Gaziano JM, Cook NR, et al.: Migraine and risk of cardiovascular disease in women. JAMA 2006, 296:283-291.
32. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al.: Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004, 113:1447-1455.
33. D'Amico D, Moschiano F, Leone M, et al.: Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke? Cephalalgia 1998, 18:618-621.
34. Herishanu Y, Rogowski O, Polliack A, Marilus R: Leukocytosis in obese individuals: possible link in patients with unexplained persistent neutrophilia. Eur J Haematol 2006, 76:516-520.
35. Matsuzawa Y: The metabolic syndrome and adipocytokines. FEBS Lett 2006, 580:2917-2921.
36. Ronti T, Lupattelli G, Mannarino E: The endocrine function of adipose tissue: an update. Clin Endocrinol 2006, 64:355-365.
37. Shoji T, Koyama H, Fukumoto S, et al.: Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis 2006, 188:190-195.
38. Siegel JM: Hypocretin (orexin): role in normal behavior and neuropathology. Annu Rev Psychol 2004, 55:25-48.
39. Kajiyama S, Kawamoto M, Shiraishi S: Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally administered orexins in diabetic neuropathic pain model rats. Brain Res 2005, 1044:76-86.
40. Baranowska B, Wolinska-Witort E, Martynska M, et al.: Plasma orexin A, orexin B, leptin, neuropeptide Y (NPY) and insulin in obese women. Neuro Endocrinol Lett 2005, 26:714.
41. Bartsch T, Levy MJ, Knight YE, Goadsby PJ: Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 2004, 109:367-378.
42. Holland PR, Akerman S, Goadsby PJ: Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther 2005, 315:1380-1385.
43. Haffner SM: Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med 2006, 119(Suppl 1):S3-S9.
44. Loevinger BL, Muller D, Alonso C, Coe CL: Metabolic syndrome in women with chronic pain. Metabolism 2007, 56:87-93.
45. Scher AI, Terwindt GM, Picavet HS, et al.: Cardiovascular risk factors and migraine: the GEM population-based study. Neurology 2005, 64:614-620.
46. Chrysohoou C, Pitsavos C, Skoumas J, et al.: The emerging anti-inflammatory role of HDL-cholesterol, illustrated in cardiovascular disease free population; the ATTICA study. Int J Cardiol 2007, 122:29-33.
47. Carnethon MR, Golden SH, Folsom AR, et al.: Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study, 1987-1998. Circulation 2003, 107:2190-2195.
48. Liatis S, Tentolouris N, Katsilambros N: Cardiac autonomic nervous system activity in obesity. Pediatr Endocrinol Rev 2004, 1(Suppl 3):476-483.
49. Peroutka SJ: Migraine: a chronic sympathetic nervous system disorder. Headache 2004 44:53-64.